Form 4 for PMVP PMV Pharmaceuticals, Inc.
Accepted 2021-07-23 00:00:00 ET · period of report 2021-07-21 · accession 0001209191-21-047988 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MI | 2021-07-23 | 2021-07-21+ | PMVP | Schroeder Thilo | Dir | S - Sale | $35.82 | -18.9K | 2.02M | -0.9% | -$676.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-07-22 | S | D | 200 | $35.61 | 2,019,657 | I See footnote | — | — | (F3) The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any. |
| 2 | Common | Common Stock | 2021-07-21 | S | D | 18,672 | $35.82 | 2,019,857 | I See footnote | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.60 to 36.08 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. (F3) The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any. |